{"id":5543,"date":"2026-03-04T16:10:00","date_gmt":"2026-03-04T16:10:00","guid":{"rendered":"https:\/\/www.barnaclinic.com\/blog\/?p=5543"},"modified":"2026-03-04T16:10:00","modified_gmt":"2026-03-04T16:10:00","slug":"obesity-and-heart-failure-tirzepatide","status":"publish","type":"post","link":"https:\/\/www.barnaclinic.com\/blog\/en\/blog\/obesity-and-heart-failure-tirzepatide\/","title":{"rendered":"Obesity and heart failure: what changes with the new European indication for tirzepatide"},"content":{"rendered":"

March 4, <\/span>World Obesity Day<\/b>, is an opportunity to remember that obesity is not an aesthetic issue but a complex chronic disease with a direct impact on metabolic and cardiovascular health. In this context, the recent <\/span>extension of the European indication for tirzepatide<\/b> \u2014the active ingredient of Mounjaro\u2014<\/span> in patients with obesity and heart failure<\/b> opens a new therapeutic scenario.<\/span><\/p>\n

To understand what this change really means, we spoke with <\/span>Dr. <\/b>Jes\u00fas Blanco<\/b><\/a>, endocrinologist at barnacl\u00ednic+ and the <\/b>Hospital Cl\u00ednic of Barcelona<\/b><\/a>, and with <\/span>Dr. Pedro Caravaca<\/a>, cardiologist specializing in heart failure at the <\/b>Hospital Cl\u00ednic of Barcelona<\/b><\/a>. Both agree on a key point: <\/span>obesity<\/b><\/a> must now be addressed as a chronic inflammatory disease with systemic consequences, especially for the heart.<\/span><\/p>\n

<\/p>\n

At barnacl\u00ednic+, we offer a\u00a0<\/b>comprehensive approach to obesity<\/b><\/a> that includes the different therapeutic options currently available \u2014from <\/span>personalized pharmacological treatment<\/span><\/a> to endoscopy or bariatric surgery\u2014 as well as <\/span>specialized evaluation and follow-up for heart failure<\/b>. Coordination between <\/span>endocrinology<\/span><\/a> and <\/span>cardiology<\/span><\/a> allows us to treat not only body weight but also the overall cardiometabolic risk of each patient.<\/span><\/p>\n

Obesity: a chronic, complex and systemic disease<\/b><\/h2>\n

Far from being an aesthetic issue, obesity is a chronic, progressive and multifactorial disease that directly affects key organs such as the heart. \u201cObesity, understood in current terms, must be considered a chronic, complex and progressive disease over time,\u201d<\/span> explains Dr. Jes\u00fas Blanco<\/a><\/strong>. For years, its management was reduced to general recommendations about diet and exercise. However, we now know that dysfunctional adipose tissue generates systemic inflammation, insulin resistance and hemodynamic alterations that favor the development of heart failure.<\/span><\/p>\n

\n

\"Dr.\u201cIt is not simply a matter of habits. There is a medical component behind a person who has been struggling with their weight for a long time.\u201d<\/h4>\n

Dr. Pedro Caravaca<\/strong><\/a>, cardiologist specializing in heart failure<\/p><\/blockquote>\n

This is why current treatment requires a full clinical evaluation, assessment of comorbidities and, when indicated, the incorporation of <\/span>obesity medications<\/b><\/a>, selected individually according to the patient\u2019s clinical profile, the presence of <\/span>type 2 diabetes<\/b><\/a>, cardiovascular risk and therapeutic goals.<\/span><\/p>\n

What is tirzepatide and what it brings to obesity treatment<\/h2>\n

Tirzepatide, whose brand name is Mounjaro, <\/span>is a dual agonist of the GIP and GLP-1 receptors<\/b> that works by modulating appetite, increasing satiety and improving glucose metabolism.<\/span><\/p>\n

It differs from Wegovy (semaglutide)<\/strong> because tirzepatide acts on both the GLP-1 receptor and the GIP receptor, while semaglutide acts only on GLP-1. Both are among the latest obesity medications<\/strong><\/a> with high clinical efficacy.<\/span><\/p>\n

\n

\"Jes\u00fas<\/h4>\n

\u201c99.9% of the prescriptions we currently make in consultation are divided between tirzepatide and semaglutide.\u201d<\/h4>\n

Dr. Jes\u00fas Blanco<\/a><\/strong>, endocrinologist<\/p><\/blockquote>\n

These drugs can be prescribed in people with a BMI above 30, or above 27 if associated conditions such as <\/span>type 2 diabetes<\/strong><\/a> or <\/span>cardiovascular disease<\/strong> are present. But the key factor is not only BMI. <\/span>\u201cAny patient with excess adiposity is potentially a candidate to benefit from these treatments.\u201d According to Dr. Caravaca, we are currently experiencing \u201ca very favorable moment\u201d in the treatment of obesity and heart failure<\/strong>.<\/span><\/p>\n

Obesity and heart failure: inflammation and a new therapeutic approach<\/b><\/h2>\n

The link between obesity, heart failure and inflammation<\/strong> is now undeniable. <\/span>For years, the so-called \u201cJ-curve\u201d of body weight in heart failure was discussed. However, when we analyze the real excess of adiposity \u2014beyond the number on the scale\u2014 the relationship becomes linear: the greater the body fat, the higher the cardiovascular risk.<\/span><\/p>\n

\n

\"Jes\u00fas<\/h4>\n

\u201cObesity is one of the drivers that modulates the development and progression of heart failure.\u201d<\/b><\/h4>\n

Dr. Jes\u00fas Blanco<\/a><\/strong>, endocrinologist<\/p><\/blockquote>\n

For years, the so-called \u201cJ-curve\u201d of body weight in heart failure was discussed. However, when we analyze the real excess of adiposity \u2014beyond the number on the scale\u2014 the relationship becomes linear: the greater the body fat, the higher the cardiovascular risk.<\/span><\/p>\n

Especially in heart failure with preserved ejection fraction, the problem is not so much the strength of the heart but stiffness and increased filling pressures.<\/span><\/p>\n

This explains why treating adiposity can become a key component of <\/span>heart failure management.<\/b> As Dr. Blanco points out, <\/span>\u201cWith the new obesity treatments, we have incorporated a new therapeutic arsenal that improves patients\u2019 clinical evolution and reduces the occurrence of clinical events.\u201d<\/b><\/p>\n

In heart failure we rarely speak about definitive cure. However, we now know that <\/span>it is possible to live with heart failure and to live many years with heart failure<\/b> when it is addressed comprehensively, acting on all the physiopathological axes involved \u2014including the metabolic inflammation associated with obesity\u2014 and optimizing each component of treatment in a personalized way.<\/span><\/p>\n

In certain profiles, tirzepatide may act as a true <\/span>heart failure drug<\/b> when obesity is a central modulating factor.<\/span><\/p>\n

Safety and monitoring: keys to success<\/b><\/h2>\n

The most common side effects of tirzepatide<\/strong> are digestive: nausea, a feeling of fullness, slower digestion or constipation, especially when dose escalation occurs too quickly. In most cases, these are temporary and manageable symptoms within appropriate medical follow-up. <\/span>As Dr. Blanco explains: \u201cPart of the medical approach is to minimize and individualize doses for each patient in order to achieve the lowest possible incidence of side effects.\u201d<\/span><\/p>\n

The key lies in personalization and gradual treatment adjustment. In patients with heart failure<\/strong>, it may also be necessary to review diuretic therapy, since these drugs can add a mild additional diuretic effect.<\/span><\/p>\n

\n

\"Dr.<\/h4>\n

\u201cThese are very safe drugs and with small adjustments it is rarely necessary to discontinue the medication.\u201d<\/b><\/h4>\n

Dr. Pedro Caravaca<\/strong><\/a>, cardiologist specializing in heart failure<\/p><\/blockquote>\n<\/blockquote>\n

We are not talking about isolated solutions or one-off interventions, but about effective therapeutic tools that, integrated into a structured multidisciplinary plan, help optimize both outcomes and long-term safety.<\/span><\/p>\n

Comprehensive treatment at barnacl\u00ednic+<\/h2>\n

Obesity<\/strong><\/a> is a chronic disease that requires a multidisciplinary approach. At barnacl\u00ednic+ we offer:<\/p>\n